All In Biotech

Drug Trial Radar · NCT00124436

Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis

Follow up Efficacy and Safety Study of BAL4979 in the Treatment of Chronic Hand Dermatitis Refractory to Topical Treatment

Last checked: Nov 20, 2026Latest source record: May 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Actual

Start

Mar 2005

Primary completion

Jan 2007

Study completion Feb 2007

Sponsor

Lead sponsor
Basilea PharmaceuticaIndustry
Sponsor type
Industry
First posted
Jul 28, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Other
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients who have been treated in study protocol BAP089 may have responded to treatment, and subsequently relapsed to \>75% of the baseline disease severity, will be investigated for response to further treatment with alitretinoin. Also, patients who have responded with mild or moderate disease will be investigated for additional treatment effect after prolongated treatment.

Conditions

  • Hand Dermatoses

Interventions

  • alitretinoinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response of chronic hand dermatitis to study treatment as assessed by Physicians Global Assessment, at week 12 or 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Thomas Ruzicka

    Düsseldorf, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.